Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM5C | P41229 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257878 | 0.91 | ALDH1A1 (0.58) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL21675612 | 0.88 | ALDH1A1 (0.52) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL13688469 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL21675625 | 0.85 | KDM4C (0.50) | ALDH1A1LMNAPKMHPGDNAMPT | |
| SCHEMBL11452609 | 0.85 | ALDH1A1 (0.61) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL21256094 | 0.84 | CYP1A2 (0.57) | ALDH1A1LMNAPKMHPGDPHF8 | |
| SCHEMBL24648935 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL22134253 | 0.83 | LMNA (0.50) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL16399076 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAPKMHPGDCNR1 | |
| SCHEMBL15248051 | 0.83 | CNR1 (0.51) | ALDH1A1LMNAPKMHPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-10751423-B2 | Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20150094312-A1 | SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885LMNA 1681/4885PKM 2004/4885 |
| US-10751423-B2 | Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer | ANXA4, ANXA3, CD47 | ALDH1A1 3501/4885LMNA 1950/4885PKM 2913/4885 |
| US-20150094312-A1 | SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE | PTGIR, ACVR1, ACVR2A | ALDH1A1 2497/4885LMNA 3678/4885PKM 792/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ALDH1A1 4236/4885LMNA 1681/4885PKM 2004/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ALDH1A1 1671/4885LMNA 4260/4885PKM 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.